Market closed
Crinetics Pharmaceuticals/$CRNX
Crinetics Pharmaceuticals shares are trading lower after the company reported a Q1 loss wider than expected.
23 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Ticker
$CRNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
437
ISIN
US22663K1079
Website
CRNX Metrics
BasicAdvanced
$3.1B
-
-$3.69
0.58
-
Price and volume
Market cap
$3.1B
Beta
0.58
52-week high
$59.95
52-week low
$24.10
Average daily volume
1M
Financial strength
Current ratio
23.045
Quick ratio
22.829
Long term debt to equity
3.364
Total debt to equity
3.904
Management effectiveness
Return on assets (TTM)
-20.46%
Return on equity (TTM)
-32.02%
Valuation
Price to revenue (TTM)
2,542.571
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
-11.495
Growth
Revenue change (TTM)
-74.11%
Earnings per share change (TTM)
-0.01%
3-year revenue growth (CAGR)
-1.22%
3-year earnings per share growth (CAGR)
9.67%
What the Analysts think about CRNX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
CRNX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRNX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRNX News
AllArticlesVideos
Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript
Seeking Alpha·16 minutes ago
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 days ago
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $3.1B as of May 10, 2025.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of May 10, 2025.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.